New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in PatientsGuruFocus · Sep 30, 2026 
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026GuruFocus · Sep 30, 2026This exchange-traded fund (ETF) endeavors to achieve investment performance, specifically in terms of price movement and income generation, that closely aligns with the EASI Tactical Growth Index, before accounting for any associated fees and expenses. Typically, the fund commits at least 80% of its total assets, including assets acquired through borrowing, directly into the securities composing this underlying index. The index itself follows a particular methodology engineered to optimize risk-adjusted returns.
